Table 3 The Cancer Genome Atlas consortium data on the incidence of genetic alterationa of DEGs in HIV-associated lung cancer by cancer type.
GENE_SYMBOL | Lung adenocarcinoma (n = 230)b | Lung adenocarcinoma (n = 522) | Lung squamous cell carcinoma (n = 177) | Breast Invasive Cancer (n = 963) | Bladder urothelial carcinoma (n = 127) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | n | % | |
FAT3 | 48 | 21% | 50 | 10% | 26 | 15% | 48 | 5% | 13 | 10% |
NFASC | 28 | 12% | 46 | 9% | 9 | 5% | 132 | 14% | 5 | 4% |
SLIT2 | 21 | 9% | 25 | 5% | 19 | 11% | 20 | 2.10% | 1 | 0.80% |
FMO2 | 21 | 9% | 37 | 7% | 15 | 8% | 96 | 10% | 20 | 16% |
ITGB8 | 18 | 8% | 30 | 6% | 10 | 6% | 26 | 2.70% | 9 | 7% |
SCARA5 | 19 | 8% | 31 | 6% | 13 | 7% | 60 | 6% | 7 | 6% |
ABCA6 | 18 | 8% | 28 | 5% | 14 | 8% | 76 | 8% | 7 | 6% |
ABCA8 | 17 | 7% | 27 | 5% | 14 | 8% | 87 | 9% | 10 | 8% |
MACC1 | 13 | 6% | 25 | 5% | 10 | 6% | 22 | 2.30% | 10 | 8% |
TACC1 | 14 | 6% | 28 | 5% | 32 | 18% | 134 | 14% | 16 | 13% |
